[go: up one dir, main page]

RU2011127055A - MEDICINAL PRODUCT FOR TREATMENT OF NEUROLOGICAL-BEHAVIORAL DEVELOPMENT DISORDERS AND METHOD OF TREATMENT OF NEUROLOGICAL-BEHAVIORAL DISORDERS OF DEVELOPMENT - Google Patents

MEDICINAL PRODUCT FOR TREATMENT OF NEUROLOGICAL-BEHAVIORAL DEVELOPMENT DISORDERS AND METHOD OF TREATMENT OF NEUROLOGICAL-BEHAVIORAL DISORDERS OF DEVELOPMENT Download PDF

Info

Publication number
RU2011127055A
RU2011127055A RU2011127055/15A RU2011127055A RU2011127055A RU 2011127055 A RU2011127055 A RU 2011127055A RU 2011127055/15 A RU2011127055/15 A RU 2011127055/15A RU 2011127055 A RU2011127055 A RU 2011127055A RU 2011127055 A RU2011127055 A RU 2011127055A
Authority
RU
Russia
Prior art keywords
antibodies
activated
potentiated form
endothelial
synthase
Prior art date
Application number
RU2011127055/15A
Other languages
Russian (ru)
Other versions
RU2536230C2 (en
Inventor
Олег Ильич Эпштейн
Original Assignee
Олег Ильич Эпштейн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Олег Ильич Эпштейн filed Critical Олег Ильич Эпштейн
Priority to RU2011127055/15A priority Critical patent/RU2536230C2/en
Priority to EA201300126A priority patent/EA030566B1/en
Priority to KR1020137003861A priority patent/KR20140014059A/en
Priority to PCT/IB2011/002350 priority patent/WO2012007845A2/en
Priority to UAA201300114A priority patent/UA112755C2/en
Priority to DE112011102411T priority patent/DE112011102411T5/en
Priority to CA2804966A priority patent/CA2804966A1/en
Priority to ES201390006A priority patent/ES2440393R1/en
Priority to PE2013000076A priority patent/PE20130398A1/en
Priority to SG2013002324A priority patent/SG187038A1/en
Priority to EEP201300006A priority patent/EE201300006A/en
Priority to PH1/2013/500144A priority patent/PH12013500144A1/en
Priority to US13/135,895 priority patent/US8987206B2/en
Priority to JP2013519175A priority patent/JP2013538186A/en
Priority to NZ606970A priority patent/NZ606970A/en
Priority to FI20135143A priority patent/FI20135143A7/en
Priority to GB1302928.5A priority patent/GB2496343B/en
Priority to NZ606767A priority patent/NZ606767A/en
Priority to GB1302649.7A priority patent/GB2495884B/en
Priority to CA2805963A priority patent/CA2805963A1/en
Priority to DE112011102358T priority patent/DE112011102358T5/en
Priority to CN2011800455232A priority patent/CN103119061A/en
Priority to CZ20130105A priority patent/CZ2013105A3/en
Priority to IT000632A priority patent/ITTO20110632A1/en
Priority to FR1156478A priority patent/FR2962911A1/en
Priority to FR1156482A priority patent/FR2962656A1/en
Priority to SG10201505561TA priority patent/SG10201505561TA/en
Priority to MX2013000543A priority patent/MX2013000543A/en
Priority to AU2011281244A priority patent/AU2011281244A1/en
Priority to EA201300139A priority patent/EA029199B1/en
Priority to JP2013520237A priority patent/JP2013535444A/en
Priority to IT000639A priority patent/ITTO20110639A1/en
Priority to MX2013000807A priority patent/MX2013000807A/en
Priority to BR112013000840A priority patent/BR112013000840A2/en
Priority to US13/135,901 priority patent/US9308275B2/en
Priority to EP11775836.7A priority patent/EP2596019A2/en
Priority to AU2011278038A priority patent/AU2011278038B2/en
Priority to EP11775838.3A priority patent/EP2593140A2/en
Priority to PH1/2013/500107A priority patent/PH12013500107A1/en
Priority to PCT/IB2011/002327 priority patent/WO2012010970A2/en
Priority to ARP110102578A priority patent/AR082247A1/en
Priority to CL2013000099A priority patent/CL2013000099A1/en
Publication of RU2011127055A publication Critical patent/RU2011127055A/en
Priority to NO20130222A priority patent/NO20130222A1/en
Priority to DKPA201370079A priority patent/DK201370079A/en
Priority to LT2013016A priority patent/LT5988B/en
Application granted granted Critical
Publication of RU2536230C2 publication Critical patent/RU2536230C2/en
Priority to US15/060,202 priority patent/US20160251448A1/en
Priority to US15/060,157 priority patent/US20160244531A1/en
Priority to JP2016135750A priority patent/JP2016216483A/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1. Лекарственное средство для лечения неврологическо-поведенческих расстройств развития, содержащее активированную - потенцированную форму антител к мозгоспецифическому белку S-100, характеризующееся тем, что выполнено в виде фармацевтической композиции и содержит в качестве дополнительного - усиливающего компонента активированную - потенцированную форму антител к эндотелиальной NO-синтазе.2. Лекарственное средство по п.1, характеризующееся тем, что фармацевтическую композицию, содержащую активированную - потенцированную форму антител к мозгоспецифическому белку S-100 и активированную - потенцированную форму антител к эндотелиальной NO-синтазе, используют для лечения синдрома дефицита внимания.3. Лекарственное средство по п.1, характеризующееся тем, что фармацевтическую композицию, содержащую активированную - потенцированную форму антител к мозгоспецифическому белку S-100 и активированную - потенцированную форму антител к эндотелиальной NO-синтазе, используют для лечения синдрома дефицита внимания и гиперактивности.4. Лекарственное средство по п.1, характеризующееся тем, что активированную - потенцированную форму антител к мозгоспецифическому белку S-100 и активированную - потенцированную форму антител к эндотелиальной NO-синтазе используют в виде активированного - потенцированного водного или водно-спиртового раствора, активность которого обусловлена процессом последовательного многократного разведения в водном или водно-спиртовом растворителе в сочетании с внешним механическим воздействием - вертикальным встряхиванием каждого разведения.5. Лекарственное средство по п.1 или 4, характеризующееся тем, что 1. A medicine for the treatment of neurological-behavioral developmental disorders, containing an activated - potentiated form of antibodies to the brain-specific protein S-100, characterized in that it is made in the form of a pharmaceutical composition and contains an activated - potentiated form of antibodies to endothelial NO as an additional - enhancing component synthase. 2. The drug according to claim 1, characterized in that the pharmaceutical composition containing the activated — potentiated form of antibodies to the brain-specific protein S-100 and the activated — potentiated form of antibodies to endothelial NO synthase is used to treat attention deficit disorder. The drug according to claim 1, characterized in that the pharmaceutical composition containing the activated — potentiated form of antibodies to the brain-specific protein S-100 and the activated — potentiated form of antibodies to endothelial NO synthase is used to treat attention deficit hyperactivity disorder. The drug according to claim 1, characterized in that the activated - potentiated form of antibodies to the brain-specific protein S-100 and the activated - potentiated form of antibodies to endothelial NO synthase are used in the form of an activated - potentiated aqueous or aqueous-alcoholic solution, the activity of which is due to the process successive multiple dilutions in an aqueous or hydroalcoholic solvent in combination with an external mechanical action - vertical shaking of each dilution. 5. The drug according to claim 1 or 4, characterized in that

Claims (14)

1. Лекарственное средство для лечения неврологическо-поведенческих расстройств развития, содержащее активированную - потенцированную форму антител к мозгоспецифическому белку S-100, характеризующееся тем, что выполнено в виде фармацевтической композиции и содержит в качестве дополнительного - усиливающего компонента активированную - потенцированную форму антител к эндотелиальной NO-синтазе.1. A medicine for the treatment of neurological-behavioral developmental disorders, containing an activated - potentiated form of antibodies to the brain-specific protein S-100, characterized in that it is made in the form of a pharmaceutical composition and contains an activated - potentiated form of antibodies to endothelial NO as an additional - enhancing component synthase. 2. Лекарственное средство по п.1, характеризующееся тем, что фармацевтическую композицию, содержащую активированную - потенцированную форму антител к мозгоспецифическому белку S-100 и активированную - потенцированную форму антител к эндотелиальной NO-синтазе, используют для лечения синдрома дефицита внимания.2. The drug according to claim 1, characterized in that the pharmaceutical composition containing the activated — potentiated form of antibodies to the brain-specific protein S-100 and the activated — potentiated form of antibodies to endothelial NO synthase is used to treat attention deficit disorder. 3. Лекарственное средство по п.1, характеризующееся тем, что фармацевтическую композицию, содержащую активированную - потенцированную форму антител к мозгоспецифическому белку S-100 и активированную - потенцированную форму антител к эндотелиальной NO-синтазе, используют для лечения синдрома дефицита внимания и гиперактивности.3. The drug according to claim 1, characterized in that the pharmaceutical composition containing the activated — potentiated form of antibodies to the brain-specific protein S-100 and the activated — potentiated form of antibodies to endothelial NO synthase is used to treat attention deficit hyperactivity disorder. 4. Лекарственное средство по п.1, характеризующееся тем, что активированную - потенцированную форму антител к мозгоспецифическому белку S-100 и активированную - потенцированную форму антител к эндотелиальной NO-синтазе используют в виде активированного - потенцированного водного или водно-спиртового раствора, активность которого обусловлена процессом последовательного многократного разведения в водном или водно-спиртовом растворителе в сочетании с внешним механическим воздействием - вертикальным встряхиванием каждого разведения.4. The drug according to claim 1, characterized in that the activated - potentiated form of antibodies to the brain-specific protein S-100 and the activated - potentiated form of antibodies to endothelial NO synthase are used in the form of an activated - potentiated aqueous or aqueous-alcoholic solution, the activity of which due to the process of successive multiple dilutions in an aqueous or hydroalcoholic solvent in combination with an external mechanical action - vertical shaking of each dilution. 5. Лекарственное средство по п.1 или 4, характеризующееся тем, что фармацевтическая композиция выполнена в твердой лекарственной форме и содержит эффективное количество гранул нейтрального носителя, насыщенного смесью водных или водно-спиртовых растворов активированной - потенцированной формы антител к мозгоспецифическому белку S-100 и активированной - потенцированной формы антител к эндотелиальной NO-синтазе, и фармацевтически приемлемые добавки.5. The drug according to claim 1 or 4, characterized in that the pharmaceutical composition is made in solid dosage form and contains an effective amount of granules of a neutral carrier saturated with a mixture of aqueous or aqueous-alcoholic solutions of an activated - potentiated form of antibodies to the brain-specific protein S-100 and activated - potentiated forms of antibodies to endothelial NO synthase, and pharmaceutically acceptable additives. 6. Лекарственное средство по п.1 или 4, характеризующееся тем, что водные или водно-спиртовые растворы активированных потенцированных форм антител к мозгоспецифическому белку S-100 и к эндотелиальной NO-синтазе получены путем многократного последовательного разведения в сочетании с внешним воздействием - вертикальным встряхиванием каждого разведения из матричных растворов аффинно очищенных антител к мозгоспецифическому белку S-100 и к эндотелиальной NO-синтазе с концентрацией 0,5÷5,0 мг/мл.6. The drug according to claim 1 or 4, characterized in that the aqueous or aqueous-alcoholic solutions of the activated potentiated forms of antibodies to the brain-specific protein S-100 and to endothelial NO synthase are obtained by repeated serial dilution in combination with an external action - vertical shaking each dilution from matrix solutions of affinity-purified antibodies to brain-specific protein S-100 and to endothelial NO synthase with a concentration of 0.5 ÷ 5.0 mg / ml 7. Лекарственное средство по п.1 или 4, характеризующееся тем, что каждый из компонентов на основе активированной - потенцированной формы антител используют в виде смеси различных, преимущественно сотенных, разведений, полученных по гомеопатической технологии.7. The drug according to claim 1 or 4, characterized in that each of the components based on the activated - potentiated form of antibodies is used as a mixture of various, mainly hundred, dilutions obtained by homeopathic technology. 8. Лекарственное средство по п.5, характеризующееся тем, что фармацевтически приемлемые добавки включают лактозу, целлюлозу микрокристаллическую и магния стеарат.8. The drug according to claim 5, characterized in that the pharmaceutically acceptable additives include lactose, microcrystalline cellulose and magnesium stearate. 9. Способ лечения неврологическо-поведенческих расстройств развития путем введения в организм активированной - потенцированной формы антител к мозгоспецифическому белку S-100, характеризующийся тем, что дополнительно одновременно и сочетанно вводят активированную - потенцированную форму антител к эндотелиальной NO-синтазе.9. A method of treating neurological-behavioral developmental disorders by introducing into the body an activated - potentiated form of antibodies to the brain-specific protein S-100, characterized in that an activated - potentiated form of antibodies to endothelial NO synthase is additionally simultaneously and simultaneously administered. 10. Способ лечения по п.9, характеризующийся тем, что активированную - потенцированную форму антител к мозгоспецифическому белку S-100 и активированную - потенцированную форму антител к эндотелиальной NO-синтазе используют для лечения синдрома дефицита внимания.10. The treatment method according to claim 9, characterized in that the activated - potentiated form of antibodies to the brain-specific protein S-100 and the activated - potentiated form of antibodies to endothelial NO synthase are used to treat attention deficit disorder. 11. Способ лечения по п.9, характеризующийся тем, что активированную - потенцированную форму антител к мозгоспецифическому белку S-100 и активированную - потенцированную форму антител к эндотелиальной NO-синтазе используют для лечения синдрома дефицита внимания и гиперактивности.11. The treatment method according to claim 9, characterized in that the activated - potentiated form of antibodies to the brain-specific protein S-100 and the activated - potentiated form of antibodies to endothelial NO synthase are used to treat attention deficit hyperactivity disorder. 12. Способ лечения по п.9, характеризующийся тем, что активированную - потенцированную форму антител к мозгоспецифическому белку S-100 и активированную - потенцированную форму антител к эндотелиальной NO-синтазе используют для лечения гиперактивности.12. The treatment method according to claim 9, characterized in that the activated - potentiated form of antibodies to the brain-specific protein S-100 and the activated - potentiated form of antibodies to endothelial NO synthase are used to treat hyperactivity. 13. Способ по п.9, характеризующийся тем, что активированную - потенцированную форму антител к мозгоспецифическому белку S-100 и активированную - потенцированную форму антител к эндотелиальной NO-синтазе используют в виде активированного - потенцированного водного или водно-спиртового раствора каждого компонента, активность которого обусловлена процессом многократного разведения в водном или водно-спиртовом растворителе в сочетании с внешним механическим воздействием - вертикальным встряхиванием каждого разведения.13. The method according to claim 9, characterized in that the activated — potentiated form of antibodies to the brain-specific protein S-100 and the activated — potentiated form of antibodies to endothelial NO synthase are used in the form of an activated — potentiated aqueous or aqueous-alcoholic solution of each component, activity which is due to the process of multiple dilutions in an aqueous or hydroalcoholic solvent in combination with an external mechanical action - vertical shaking of each dilution. 14. Способ лечения по п.9, характеризующийся тем, что используют приготовленные в виде единого лекарственного препарата - одной лекарственной формы смесь различных разведений антител к мозгоспецифическому белку S-100 в сочетании со смесью различных разведений антител к эндотелиальной NO-синтазе, приготовленных по гомеопатической технологии. 14. The treatment method according to claim 9, characterized in that a mixture of different dilutions of antibodies to the brain-specific protein S-100 in combination with a mixture of different dilutions of antibodies to endothelial NO synthase prepared according to homeopathic prepared in the form of a single drug is used technologies.
RU2011127055/15A 2010-05-20 2011-07-01 Therapeutic agent for treating neurological behaviour disorders and method of treating neurological behaviour development disorders RU2536230C2 (en)

Priority Applications (48)

Application Number Priority Date Filing Date Title
RU2011127055/15A RU2536230C2 (en) 2011-07-01 2011-07-01 Therapeutic agent for treating neurological behaviour disorders and method of treating neurological behaviour development disorders
EA201300126A EA030566B1 (en) 2010-07-15 2011-07-15 Method of increasing therapeutic effectiveness of an activated-potentiated form of an antibody to an endogenous biological molecule and pharmaceutical composition
KR1020137003861A KR20140014059A (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
PCT/IB2011/002350 WO2012007845A2 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
UAA201300114A UA112755C2 (en) 2010-07-21 2011-07-15 METHOD OF TREATMENT OF ATTENTION AND HYPERACTIVITY DEFICIENCY SYNDROME
DE112011102411T DE112011102411T5 (en) 2010-07-21 2011-07-15 A method of treating attention deficit hyperactivity disorder
CA2804966A CA2804966A1 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
ES201390006A ES2440393R1 (en) 2010-07-15 2011-07-15 A METHOD FOR INCREASING THE EFFECT OF A POTENTIATED ACTIVATED FORM OF AN ANTIBODY
PE2013000076A PE20130398A1 (en) 2010-07-15 2011-07-15 A METHOD TO INCREASE THE EFFECT OF AN ACTIVE ENHANCED FORM OF AN ANTIBODY
SG2013002324A SG187038A1 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
EEP201300006A EE201300006A (en) 2010-07-15 2011-07-15 A pharmaceutical composition for enhancing the effect of an activated and potentiated form of an antibody
PH1/2013/500144A PH12013500144A1 (en) 2010-07-21 2011-07-15 A method of treating attention deficit hyperactivity disorder
US13/135,895 US8987206B2 (en) 2010-07-21 2011-07-15 Method of treating attention deficit hyperactivity disorder
JP2013519175A JP2013538186A (en) 2010-07-15 2011-07-15 Method for increasing the effect of activation-enhancing antibodies
NZ606970A NZ606970A (en) 2010-07-21 2011-07-15 A method of treating attention deficit hyperactivity disorder
FI20135143A FI20135143A7 (en) 2010-05-20 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
GB1302928.5A GB2496343B (en) 2010-07-21 2011-07-15 A method of treating attention deficit hyperactivity disorder
NZ606767A NZ606767A (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
GB1302649.7A GB2495884B (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
CA2805963A CA2805963A1 (en) 2010-07-21 2011-07-15 A method of treating attention deficit hyperactivity disorder
DE112011102358T DE112011102358T5 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
CN2011800455232A CN103119061A (en) 2010-07-21 2011-07-15 Ways to treat attention deficit hyperactivity disorder
CZ20130105A CZ2013105A3 (en) 2010-07-15 2011-07-15 Method of increasing effect of antibody activated potentiated form
IT000632A ITTO20110632A1 (en) 2010-07-21 2011-07-15 METHOD TO TREAT DISORDER FROM DEFICIT ATTENTION AND HYPERACTIVITY
FR1156478A FR2962911A1 (en) 2010-07-21 2011-07-15 PHARMACEUTICAL ASSOCIATION COMPOSITION FOR USE IN A METHOD FOR TREATING HYPERACTIVITY DISORDER WITH DEFICIT ATTENTION
FR1156482A FR2962656A1 (en) 2010-07-15 2011-07-15 METHOD FOR INCREASING THE EFFECT OF AN ACTIVATED-POTENTIALIZED FORM OF ANTIBODY
SG10201505561TA SG10201505561TA (en) 2010-07-15 2011-07-15 A Method Of Increasing The Effect Of An Activated-Potentiated Form Of An Antibody
MX2013000543A MX2013000543A (en) 2010-07-15 2011-07-15 Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract.
AU2011281244A AU2011281244A1 (en) 2010-07-21 2011-07-15 A method of treating attention deficit hyperactivity disorder
EA201300139A EA029199B1 (en) 2010-07-21 2011-07-15 Combination pharmaceutical composition for treating attention deficit hyperactivity disorder and methods of treating attention deficit hyperactivity disorder
JP2013520237A JP2013535444A (en) 2010-07-21 2011-07-15 How to treat attention deficit hyperactivity disorder
IT000639A ITTO20110639A1 (en) 2010-07-15 2011-07-15 METHOD TO INCREASE THE EFFECT OF AN ACTIVE-ENHANCED SHAPE OF AN ANTI-BODY
MX2013000807A MX2013000807A (en) 2010-07-21 2011-07-15 A method of treating attention deficit hyperactivity disorder.
BR112013000840A BR112013000840A2 (en) 2010-07-15 2011-07-15 method for enhancing the effect of potentiated activated form of antibody to biological endogenous molecule, pharmaceutical composition and use of combination of endogenous biological molecule with potentiated activated form of antibody to endothelial synthase.
US13/135,901 US9308275B2 (en) 2010-07-15 2011-07-15 Method of increasing the effect of an activated-potentiated form of an antibody
EP11775836.7A EP2596019A2 (en) 2010-07-21 2011-07-15 A method of treating attention deficit hyperactivity disorder
AU2011278038A AU2011278038B2 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
EP11775838.3A EP2593140A2 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
PH1/2013/500107A PH12013500107A1 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
PCT/IB2011/002327 WO2012010970A2 (en) 2010-07-21 2011-07-15 A method of treating attention deficit hyperactivity disorder
ARP110102578A AR082247A1 (en) 2010-07-15 2011-07-18 A METHOD FOR INCREASING THE EFFECTS OF A POTENTIATED ACTIVATED FORM OF AN ANTIBODY
CL2013000099A CL2013000099A1 (en) 2010-07-15 2013-01-10 A method of increasing the effect of an potentiated active form of an antibody to an endogenous biological molecule, comprising the combination of the endogenous biological molecule with an enhanced active form of an endoltelial non-synthase antibody; composition that understands it.
NO20130222A NO20130222A1 (en) 2010-07-15 2013-02-08 Process for increasing the effect of an activated-potentiated form of an antibody
DKPA201370079A DK201370079A (en) 2010-07-15 2013-02-14 A method of increasing the effect of an activated-potentiated form of an antibody
LT2013016A LT5988B (en) 2010-07-15 2013-02-14 A method of increasing the effect of an activated-potentiated form of an antibody
US15/060,202 US20160251448A1 (en) 2010-07-15 2016-03-03 Method of increasing the effect of an activated-potentiated form of an antibody
US15/060,157 US20160244531A1 (en) 2010-07-15 2016-03-03 Method of increasing the effect of an activated-potentiated form of an antibody
JP2016135750A JP2016216483A (en) 2010-07-15 2016-07-08 Method for increasing the effect of activation-enhancing antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2011127055/15A RU2536230C2 (en) 2011-07-01 2011-07-01 Therapeutic agent for treating neurological behaviour disorders and method of treating neurological behaviour development disorders

Publications (2)

Publication Number Publication Date
RU2011127055A true RU2011127055A (en) 2013-01-10
RU2536230C2 RU2536230C2 (en) 2014-12-20

Family

ID=48795257

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011127055/15A RU2536230C2 (en) 2010-05-20 2011-07-01 Therapeutic agent for treating neurological behaviour disorders and method of treating neurological behaviour development disorders

Country Status (1)

Country Link
RU (1) RU2536230C2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025088452A1 (en) 2023-10-24 2025-05-01 Epshtein Oleg Ilyich Artificial substance and method of its preparation
CH721975A1 (en) 2024-07-15 2026-01-30 Ilyich Epshtein Oleg Methods for the preservation of cosmetic and therapeutic cosmetic products
CH721974A1 (en) 2024-07-15 2026-01-30 Ilyich Epshtein Oleg Methods for the manufacture of pharmaceutical preparations that alter the influence of external physical effects on the body
CH721976A1 (en) 2024-07-15 2026-01-30 Ilyich Epshtein Oleg Methods for obtaining biopreparations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562629B1 (en) * 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
RU2156621C1 (en) * 1999-03-04 2000-09-27 Эпштейн Олег Ильич Neurotropic drug
RU2195317C1 (en) * 2001-04-18 2002-12-27 Эпштейн Олег Ильич Method of correcting pathologic immune reactions and therapeutic agent

Also Published As

Publication number Publication date
RU2536230C2 (en) 2014-12-20

Similar Documents

Publication Publication Date Title
RU2010133048A (en) MEDICINAL PRODUCT AND METHOD FOR PREVENTION OF HIV INFECTION, PREVENTION AND TREATMENT OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV, INCLUDING AIDS
RU2010133045A (en) MEDICINAL PRODUCT AND METHOD FOR PREVENTION OF HIV INFECTION, PREVENTION AND TREATMENT OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV, INCLUDING AIDS
RU2011127055A (en) MEDICINAL PRODUCT FOR TREATMENT OF NEUROLOGICAL-BEHAVIORAL DEVELOPMENT DISORDERS AND METHOD OF TREATMENT OF NEUROLOGICAL-BEHAVIORAL DISORDERS OF DEVELOPMENT
RU2013154071A (en) MEDICINAL PRODUCT AND METHOD FOR TREATMENT OF HEAD-WAYS
RU2013154072A (en) MEDICINE FOR TREATMENT OF KINETOSIS AND METHOD OF TREATMENT OF KINETOSIS
RU2010130358A (en) MEDICINE FOR TREATMENT OF ATTENTION DEFICIENCY SYNDROME AND METHOD FOR TREATMENT OF ATTENTION DEFICIENCY SYNDROME
RU2011127052A (en) METHOD FOR TREATING THE HEAD-VARIABLE OF VARIOUS GENESIS, KINETOSIS AND VEGETOVASCULAR DYSTONIA (OPTIONS) AND MEDICINAL PRODUCT
RU2011127059A (en) NEUROTROPIC MEDICINE AND METHOD OF TREATMENT OF ORGANIC DISEASES OF THE NERVOUS SYSTEM, PSYCHOORGANIC SYNDROME AND ENCEPHALOPATHY OF VARIOUS GENESIS
RU2010133051A (en) COMPREHENSIVE MEDICINE FOR TREATMENT OF INFLUENZA TREATMENT OF VARIOUS TYPES
RU2010133047A (en) INTEGRATED MEDICINE AND METHOD FOR PREVENTION OF HIV INFECTION, PREVENTION AND TREATMENT OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV, INCLUDING AIDS
RU2011127058A (en) MEDICINE FOR TREATMENT OF ALZHEIMER'S DISEASE AND METHOD OF TREATMENT OF ALZHEIMER'S DISEASE
RU2010133053A (en) INTEGRATED MEDICINE FOR TREATMENT OF VIRAL DISEASES AND METHOD OF TREATMENT OF VIRAL DISEASES
RU2010130355A (en) MEDICINAL PRODUCT AND METHOD FOR TREATMENT OF ORGANIC DISEASES OF THE NERVOUS SYSTEM, PSYCHOORGANIC SYNDROME AND ENCEPHALOPATHY OF VARIOUS GENESIS
RU2013154070A (en) METHOD FOR TREATMENT OF VEGETAIN-VASCULAR DISTONIA AND MEDICINAL PRODUCT
RU2010130353A (en) MEDICINE FOR TREATMENT OF ALZHEIMER'S DISEASE AND METHOD OF TREATMENT OF ALZHEIMER'S DISEASE
RU2010130356A (en) MEDICINAL PRODUCT AND METHOD FOR TREATMENT OF VEGETO-VASCULAR DYSTONIA, VERTAIN SYNDROME OF VARIOUS GENESIS AND KINETOSIS
RU2013154073A (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING A PATHOLOGICAL SYNDROME
RU2011124809A (en) MEDICINE FOR TREATMENT OF PATHOLOGICAL SYNDROME AND METHOD FOR TREATING FUNCTIONAL INTESTINAL DISORDERS
RU2016145411A (en) The combination of brexpiprazole and nalmefene, and its use for the treatment of the syndrome of chemical dependence
RU2011127056A (en) MEDICINAL PRODUCT FOR TREATMENT OF PATHOLOGICAL SYNDROME AND METHOD FOR TREATING MULTIPLE SCLEROSIS
RU2010129295A (en) MEDICINAL PRODUCT FOR TREATING PROSTATE DISEASES AND METHOD FOR TREATING PROSTATE DISEASES
RU2013152871A (en) DIABETES TREATMENT METHOD AND COMBINED MEDICINE
RU2010130350A (en) METHOD FOR TREATING DEPENDENCE ON PSYCHOACTIVE SUBSTANCES, ALCOHOLISM AND TOBACCO SMOKING AND MEDICINAL PRODUCT FOR TREATING DEPENDENCE ON PSYCHOACTIVE SUBSTANCES, ALCOHOLISM AND TOBACCO SMOKING
RU2010129294A (en) MEDICINE FOR TREATMENT OF ERECTILE DYSFUNCTIONS AND METHOD OF TREATMENT OF ERECTILE DYSFUNCTIONS
RU2013152874A (en) MEDICINE

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20180702